Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 6/20 | 0.54 |
| ▸ | AHR | P35869 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.45 |
| ▸ | GPR142 | Q7Z601 | 2/20 | 0.45 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.44 |
| ▸ | APP | P05067 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17957763 | 1.00 | RIPK1 (0.54) | RIPK1AHRALDH1A1KDM4EPIK3CA | |
| SCHEMBL7949587 | 0.85 | NOTUM (0.58) | RIPK1AHRALDH1A1KDM4EPIK3CA | |
| SCHEMBL31171764 | 0.83 | NOTUM (0.44) | RIPK1AHRALDH1A1NOTUMTHRB | |
| SCHEMBL29471404 | 0.81 | CREBBP (0.57) | — | |
| SCHEMBL21505115 | 0.81 | ALDH1A1 (0.50) | RIPK1AHRALDH1A1KDM4EPIK3CA | |
| SCHEMBL18794297 | 0.81 | KDM4E (0.53) | RIPK1AHRALDH1A1KDM4ENOTUM | |
| SCHEMBL15055636 | 0.78 | RIPK1 (0.46) | RIPK1PIK3CAGPR142KMT2A | |
| SCHEMBL3789225 | 0.78 | RIPK1 (0.46) | RIPK1PIK3CAGPR142 | |
| SCHEMBL31046947 | 0.78 | MAPK1 (0.57) | RIPK1AHRALDH1A1KDM4E | |
| SCHEMBL11985662 | 0.78 | MAPK1 (0.57) | RIPK1AHRALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11279681-B2 | 3-alkyl bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors | VALO HEALTH, INC. (US) | 2022-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11279681-B2 | 3-alkyl bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors | HDAC1, HDAC4, HDAC2 | RIPK1 3664/4885AHR 1222/4885ALDH1A1 1465/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.